Analysts Set Cerulean Pharma Inc (CERU) Price Target at $3.00

Cerulean Pharma Inc (NASDAQ:CERU) has been assigned a consensus recommendation of “Hold” from the seven analysts that are presently covering the company. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $3.00.

Separately, Zacks Investment Research cut shares of Cerulean Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 11th.

Shares of Cerulean Pharma (NASDAQ:CERU) traded down 1.077% on Tuesday, reaching $0.643. 314,766 shares of the company’s stock were exchanged. Cerulean Pharma has a 12 month low of $0.63 and a 12 month high of $4.15. The firm’s 50-day moving average price is $1.19 and its 200 day moving average price is $0.97. The company’s market cap is $18.66 million.

COPYRIGHT VIOLATION NOTICE: This article was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at

About Cerulean Pharma

Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

5 Day Chart for NASDAQ:CERU

Receive News & Ratings for Cerulean Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply